Stockscreener 앱 받기
71.68
7.58%
-5.88
시장 영업 전:
72.04
0.36
+0.50%
전일 마감가:
$77.56
열려 있는:
$77.56
하루 거래량:
6.05M
Relative Volume:
3.64
시가총액:
$7.60B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
56.89
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
-8.91%
1개월 성능:
-1.50%
6개월 성능:
+21.06%
1년 성능:
+137.59%
1일 변동 폭
$70.00
$86.20
1주일 범위
$70.00
$86.20
52주 변동 폭
$28.04
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
71.68 | 8.15B | 628.56M | 141.82M | 142.60M | 1.26 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday - Yahoo
Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatment - Yahoo Finance
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with - GuruFocus
Corcept shares rise on positive Phase 3 trial results By Investing.com - Investing.com Nigeria
Corcept Therapeutics (CORT) Shows Positive Phase 3 Trial Results for Ovarian Cancer Treatment | CORT Stock News - GuruFocus
Corcept shares rise on positive Phase 3 trial results - Investing.com Australia
Relacorilant shows promise for ovarian cancer treatment - Investing.com
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today - Benzinga
Zacks Research Has Negative Outlook for CORT Q2 Earnings - Defense World
Bank of America Corp DE Cuts Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Nuveen Asset Management LLC - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Holdings Lessened by Cetera Investment Advisers - Defense World
Abortion Drugs Market Deep Research and Growth in Future Scope - openPR.com
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT) - FinancialContent
Director, Oncology Patient Support OperationsRedwood CityCorcept Therapeutics - Ladders
Deutsche Bank AG Buys 24,051 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed - Yahoo Finance
Critical Review: Kaya (OTCMKTS:KAYS) vs. Corcept Therapeutics (NASDAQ:CORT) - Defense World
Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight - Yahoo Finance
Cushing's Syndrome Market Growth Drivers and Industry Insights - openPR.com
Corcept Therapeutics (NASDAQ:CORT) Downgraded to “Hold” Rating by StockNews.com - Defense World
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Is Posting Promising Earnings But The Good News Doesn’t Stop There - Yahoo Finance
Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now - Insider Monkey
11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey
Investor Network: Corcept Therapeutics Incorporated. to Host Earnings Call - ACCESS Newswire
Insider Sell: William Guyer Sells Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
HC Wainwright Has Pessimistic Outlook of CORT Q2 Earnings - Defense World
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Price Target at $143.25 - Defense World
Corcept Therapeutics chief development officer sells $524,652 in stock By Investing.com - Investing.com India
Corcept Therapeutics chief development officer sells $524,652 in stock - Investing.com Australia
High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
HC Wainwright Has Lowered Expectations for Corcept Therapeutics (NASDAQ:CORT) Stock Price - Defense World
Corcept Therapeutics (NASDAQ:CORT) Raised to Buy at StockNews.com - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2025 Earnings Call Transcript - Insider Monkey
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall - MSN
Corcept Therapeutics price target lowered to $135 from $150 at Truist - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Down on Insider Selling - Defense World
Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS - Yahoo Finance
Corcept Therapeutics (CORT) Faces Price Target Cut Amid Revenue Concerns | CORT Stock News - GuruFocus
Assessing Corcept Therapeutics: Insights From 9 Financial Analysts - Benzinga
Truist Cuts Price Target on Corcept Therapeutics to $135 From $150, Keeps Buy Rating - marketscreener.com
H.C. Wainwright cuts Corcept Therapeutics target to $145 By Investing.com - Investing.com Nigeria
Corcept Therapeutics (CORT) Receives Revised Price Target from A - GuruFocus
Corcept Therapeutics (CORT) Receives Revised Price Target from Analyst | CORT Stock News - GuruFocus
Corcept Therapeutics (CORT) Maintains Buy Rating Amid Revised Pr - GuruFocus
Corcept Therapeutics (CORT) Maintains Buy Rating Amid Revised Price Target | CORT Stock News - GuruFocus
Corcept Therapeutics Inc Q1 2025 Earnings: EPS of $0.17 Beats Es - GuruFocus
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS A - GuruFocus
Corcept Therapeutics (CORT) Pre-Earnings Options Activity Sugges - GuruFocus
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.48%
자본화:
|
볼륨(24시간):